Download PDF
CC BY-NC-ND 4.0 · Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery 2019; 38(01): 025-030
DOI: 10.1055/s-0039-1678561
Original Article | Artigo Original
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Effect of Albendazole Treatment in an Experimental Model of Neurocysticercosis-Induced Hydrocephalus

Efeito do tratamento com albendazol num modelo experimental de hidrocefalia induzida por neurocisticercose
Marcelo Ortolani Fogaroli
1   Department of Neurology, Psychology and Psychiatry, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
,
Marcelo Augusto Chiantelli Oliveira
1   Department of Neurology, Psychology and Psychiatry, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
,
Pedro Tadao Hamamoto Filho
1   Department of Neurology, Psychology and Psychiatry, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
,
Marcelo Padovani de Toledo Moraes
1   Department of Neurology, Psychology and Psychiatry, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
,
Luiz Carlos Vulcano
1   Department of Neurology, Psychology and Psychiatry, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
,
Rodrigo Bazan
1   Department of Neurology, Psychology and Psychiatry, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
,
Marco Antônio Zanini
1   Department of Neurology, Psychology and Psychiatry, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
,
Agnès Fleury
2   Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico
› Author Affiliations
Further Information

Publication History

06 July 2018

08 January 2019

Publication Date:
21 February 2019 (online)

   Permissions and Reprints

Corrected by:

Erratum - Effect of Albendazole Treatment in an Experimental Model of Neurocysticercosis-Induced HydrocephalusArquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery 2019; 38(01): 077-077
DOI: 10.1055/s-0039-1683954

Abstract

Hydrocephalus is a major concern in neurocysticercosis (NCC), and its management is more challenging than that of hydrocephalus caused by other etiologies. Even though albendazole is a well-established drug for the treatment of NCC, the death of the parasites may worsen the clinical symptoms and eventually, deteriorate the course of hydrocephalus. The aim of this study was to analyze the effects of treatment with albendazole on the course of hydrocephalus as well as on animal behavior in a rat model of NCC-induced hydrocephalus in order to verify whether the course of hydrocephalus and the animal behavior were changed. Ventricle volumes before and after treatment showed a slight but non-statistically significant difference (168.11 mm3 versus 184.98 mm3, p = 0.45). The distribution and location of the cysts were unaffected. In addition, the behavioral patterns before and after the treatment were not significantly different, as assessed by the open field test. On histologic assessment, mononuclear leukocyte infiltration was present in diverse sites, such as the perivascular and peri-ependymal regions, choroid plexus, and meningeal membranes. A positive correlation was found between the degree of ventricle enlargement and tissue damage. Further studies with long-term comparisons are required.

Resumo

A hidrocefalia é uma das principais complicações da neurocisticercose (NCC), e seu manejo pode ser mais desafiador do que outras forma de hidrocefalia. Apesar de o albendazol ser uma droga bem estabelecida para o tratamento da NCC, a morte do parasitas pode agravar os sintomas clínicos e, eventualmente, deteriorar o curso de hidrocefalia. O objetivo deste estudo foi analisar os efeitos do tratamento com albendazol no curso da hidrocefalia, bem como no comportamento animal em um modelo de hidrocefalia induzida por NCC em ratos. Na análise do volumes ventricular antes e depois do tratamento, houve uma diferença leve, mas não estatisticamente significativa (168,11 mm3 versus 184,98 mm3, p = 0,45). A distribuição e localização dos cistos não foram afetadas.

Além disso, os padrões comportamentais antes e após o tratamento também não foram significativamente diferentes. A avaliação histológica mostrou infiltração leucocitária mononuclear em diversos sítios, como nas regiões perivascular e periependimária, plexo coróide e meninges. Uma correlação positiva foi encontrada entre o grau de aumento do ventrículo e dano tecidual. Mais estudos com comparações de longo prazo são necessários para melhor compreensão da possível deterioração clínica da hidrocefalia por NCC quando do tratamento clínico.

Keywords

hydrocephalus - neurocysticercosis - albendazole - experimental design

Palavras-chave

hidrocefalia - neurocisticercose - albendazol - desenho experimental
 

  • References

  • 1 Martins-Melo FR, Ramos Jr AN, Cavalcanti MG, Alencar CH, Heukelbach J. Neurocysticercosis-related mortality in Brazil, 2000-2011: Epidemiology of a neglected neurologic cause of death. Acta Trop 2016; 153: 128-136
    CrossrefPubMedGoogle Scholar
  • 2 Singh BB, Khatkar MS, Gill JPS, Dhand NK. Estimation of the health and economic burden of neurocysticercosis in India. Acta Trop 2017; 165: 161-169
    CrossrefPubMedGoogle Scholar
  • 3 Fabiani S, Bruschi F. Neurocysticercosis in Europe: Still a public health concern not only for imported cases. Acta Trop 2013; 128 (01) 18-26
    CrossrefPubMedGoogle Scholar
  • 4 O'Neal SE, Flecker RH. ; ONeal SE. Hospitalization frequency and charges for neurocysticercosis, United States, 2003-2012. Emerg Infect Dis 2015; 21 (06) 969-976
    CrossrefPubMedGoogle Scholar
  • 5 Marcin Sierra M, Arroyo M, Cadena Torres M. , et al. Extraparenchymal neurocysticercosis: Demographic, clinicoradiological, and inflammatory features. PLoS Negl Trop Dis 2017; 11 (06) e0005646
    CrossrefPubMedGoogle Scholar
  • 6 Fleury A, Carrillo-Mezo R, Flisser A, Sciutto E, Corona T. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 2011; 9 (01) 123-133
    CrossrefPubMedGoogle Scholar
  • 7 Bazan R, Hamamoto Filho PT, Luvizutto GJ. , et al. Clinical symptoms, imaging features and cyst distribution in the cerebrospinal fluid compartments in patients with extraparenchymal neurocysticercosis. PLoS Negl Trop Dis 2016; 10 (11) e0005115
    CrossrefPubMedGoogle Scholar
  • 8 Kelley R, Duong DH, Locke GE. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery 2002; 50 (04) 757-761 , discussion 761–762
    CrossrefPubMedGoogle Scholar
  • 9 Colli BO, Carlotti Jr CG, Assirati Jr JA, Machado HR, Valença M, Amato MCM. Surgical treatment of neurocysticercosis: long-term results and prognostic factors. Neurosurg Focus 2002; 12: 1-13
    PubMedGoogle Scholar
  • 10 Agapejev S, Pouza AF, Bazan R, Faleiros ATS. [Clinical and evolutive aspects of hydrocephalus in neurocysticercosis]. Arq Neuropsiquiatr 2007; 65 (3A): 674-680
    CrossrefPubMedGoogle Scholar
  • 11 Paiva ALC, Araujo JLV, Ferraz VR. , et al. Surgical treatment of neurocysticercosis. Retrospective cohort study and an illustrative case report. Sao Paulo Med J 2017; 135 (02) 146-149
    CrossrefPubMedGoogle Scholar
  • 12 Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol 2014; 13 (12) 1202-1215
    CrossrefPubMedGoogle Scholar
  • 13 Del Brutto OH. Clinical management of neurocysticercosis. Expert Rev Neurother 2014; 14 (04) 389-396
    CrossrefPubMedGoogle Scholar
  • 14 Alvarez JI, Mishra BB, Gundra UM, Mishra PK, Teale JM. Mesocestoides corti intracranial infection as a murine model for neurocysticercosis. Parasitology 2010; 137 (03) 359-372
    CrossrefPubMedGoogle Scholar
  • 15 Matos-Silva H, Reciputti BP, Paula EC. , et al. Experimental encephalitis caused by Taenia crassiceps cysticerci in mice. Arq Neuropsiquiatr 2012; 70 (04) 287-292
    CrossrefPubMedGoogle Scholar
  • 16 Fleury A, Trejo A, Cisneros H. , et al. Taenia solium: development of an experimental model of porcine neurocysticercosis. PLoS Negl Trop Dis 2015; 9 (08) e0003980
    CrossrefPubMedGoogle Scholar
  • 17 Verastegui MR, Mejia A, Clark T. , et al. Novel rat model for neurocysticercosis using Taenia solium. Am J Pathol 2015; 185 (08) 2259-2268
    CrossrefPubMedGoogle Scholar
  • 18 Milhomem AC, Souza AJS, Silva HM. , et al. Histopathologic aspects of experimental cysticercosis and in situ cytokines profile in C57BL/6 mice. Arq Neuropsiquiatr 2018; 76 (05) 339-345
    CrossrefPubMedGoogle Scholar
  • 19 Alroy KA, Arroyo G, Gilman RH. , et al. Carotid T solium oncosphere infection: a novel porcine neurocysticercosis model. Am J Trop Hyg 2018
    PubMedGoogle Scholar
  • 20 Hamamoto Filho PT, Fabro AT, Rodrigues MV. , et al. Taenia crassiceps injection into the subarachnoid space of rats simulates radiological and morphological features of racemose neurocysticercosis. Childs Nerv Syst 2017; 33 (01) 119-123
    CrossrefPubMedGoogle Scholar
  • 21 Hamamoto Filho PT, Zanini MA, Botta FP. , et al. Development of an experimental model of neurocysticercosis-induced hydrocephalus. Pilot study. Acta Cir Bras 2015; 30 (12) 819-823
    CrossrefPubMedGoogle Scholar
  • 22 Agapejev S. Neurocysticercosis: the enigmatic disease. Cent Nerv Syst Agents Med Chem 2011; 11 (04) 261-284
    CrossrefPubMedGoogle Scholar
  • 23 Arora N, Tripathi S, Kumar P, Mondal P, Mishra A, Prasad A. Recent advancements and new perspectives in animal models for Neurocysticercosis immunopathogenesis. Parasite Immunol 2017; 39 (07) e12439
    CrossrefPubMedGoogle Scholar
  • 24 White Jr AC, Coyle CM, Rajshekhar V. , et al. Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2018; 66 (08) 1159-1163
    CrossrefPubMedGoogle Scholar
  • 25 Garcia HH, Gonzalez AE, Gilman RH. Cysticercosis of the central nervous system: how should it be managed?. Curr Opin Infect Dis 2011; 24 (05) 423-427
    CrossrefPubMedGoogle Scholar
  • 26 Garcia HH, Gonzales I, Lescano AG. , et al; Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis 2014; 14 (08) 687-695
    CrossrefPubMedGoogle Scholar
  • 27 Carpio A, Kelvin EA, Bagiella E. , et al; Ecuadorian Neurocysticercosis Group. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79 (09) 1050-1055
    CrossrefPubMedGoogle Scholar
  • 28 García HH, Evans CAW, Nash TE. , et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002; 15 (04) 747-756
    CrossrefPubMedGoogle Scholar
  • 29 Göngora-Rivera F, Soto-Hernández JL, González Esquivel D. , et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 2006; 66 (03) 436-438
    CrossrefPubMedGoogle Scholar
  • 30 Mahale RR, Mehta A, Rangasetty S. Extraparenchymal (racemose) neurocysticercosis and its multitude manifestations: a comprehensive review. J Clin Neurol 2015; 11 (03) 203-211
    CrossrefPubMedGoogle Scholar